{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:18:20Z","timestamp":1793513900593,"version":"4.5.0"},"reference-count":352,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["IIRS-23-004"],"award-info":[{"award-number":["IIRS-23-004"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2027365"],"award-info":[{"award-number":["2027365"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.pharmr.2025.100087","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:00:11Z","timestamp":1755550811000},"page":"100087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy"],"prefix":"10.1016","volume":"77","author":[{"given":"Busra","family":"Kaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3606-0718","authenticated-orcid":false,"given":"Devina","family":"Laurencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maseeha Farha","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahan Gholam","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendiran","family":"Dharmasivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-3274","authenticated-orcid":false,"given":"Des R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pharmr.2025.100087_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100087_bib3","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pharmr.2025.100087_bib4","article-title":"Health care expenditure burden of cancer care in the United States","volume":"56","author":"Park","year":"2019","journal-title":"Inquiry"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12962-022-00408-6","article-title":"A systemmatic literature review on indirect costs of women with breast cancer","volume":"20","author":"Mohammadpour","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/jnci\/djy177","article-title":"Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review","volume":"110","author":"Carreira","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100087_bib7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk factors and preventions of breast cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int J Biol Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib8","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/nu11071514","article-title":"Nutrition and breast cancer: a literature review on prevention, treatment and recurrence","volume":"11","author":"De Cicco","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmr.2025.100087_bib9","series-title":"Breast Cancer","author":"Alkabban","year":"2023"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib11","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1002\/cam4.2474","article-title":"Are 90% of deaths from cancer caused by metastases?","volume":"8","author":"Dillek\u00e5s","year":"2019","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","article-title":"Cancer metastases: challenges and opportunities","volume":"5","author":"Guan","year":"2015","journal-title":"Acta Pharm Sin B"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2025.100087_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1615\/CritRevOncog.v18.i1-2.40","article-title":"On the origin of cancer metastasis","volume":"18","author":"Seyfried","year":"2013","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","article-title":"The lingering mysteries of metastatic recurrence in breast cancer","volume":"124","author":"Riggio","year":"2021","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188871","article-title":"The role of the NDRG1 in the pathogenesis and treatment of breast cancer","volume":"1878","author":"Zhao","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","article-title":"Molecular subtypes of breast cancer: a review for breast radiologists","volume":"3","author":"Johnson","year":"2021","journal-title":"J Breast Imaging"},{"key":"10.1016\/j.pharmr.2025.100087_bib17","series-title":"Breast Cancer","first-page":"31","article-title":"Subtypes of breast cancer","author":"Orrantia-Borunda","year":"2022"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2014.05.005","article-title":"Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome","volume":"15","author":"Matro","year":"2015","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.breast.2011.07.008","article-title":"Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry","volume":"21","author":"Park","year":"2012","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib20","doi-asserted-by":"crossref","first-page":"R337","DOI":"10.1530\/ERC-16-0121","article-title":"Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies","volume":"23","author":"Murphy","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib21","article-title":"Role of estrogen receptor signaling in breast cancer metastasis","volume":"2012","author":"Saha Roy","year":"2012","journal-title":"Int J Breast Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0039-128X(02)00110-1","article-title":"Estrogen receptor phosphorylation","volume":"68","author":"Lannigan","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.pharmr.2025.100087_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.pharmr.2025.100087_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106806","article-title":"Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer","volume":"193","author":"Shehadeh-Tout","year":"2023","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3892\/etm.2021.9972","article-title":"PI3K\/AKT\/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (review)","volume":"21","author":"Miricescu","year":"2021","journal-title":"Exp Ther Med"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib26","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1158\/0008-5472.CAN-09-3834","article-title":"Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells","volume":"70","author":"Chakravarty","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.6026\/97320630012135","article-title":"Molecular mechanisms and mode of tamoxifen resistance in breast cancer","volume":"12","author":"Ali","year":"2016","journal-title":"Bioinformation"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib29","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/carcin\/bgt163","article-title":"Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmr.2025.100087_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fendo.2018.00492","article-title":"The androgen receptor in breast cancer","volume":"9","author":"Giovannelli","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100087_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/DDDT.S336643","article-title":"The role of progesterone receptors in breast cancer","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pharmr.2025.100087_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.910978","article-title":"Prolactin: the third hormone in breast cancer","volume":"13","author":"Schuler","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100087_bib33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.steroids.2016.09.004","article-title":"Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor \u03b1 (ER) and progesterone receptor (PR) genomic action at ER\/PR target genes","volume":"114","author":"Diep","year":"2016","journal-title":"Steroids"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100087_bib34","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1242\/jcs.039131","article-title":"Transcriptional regulation of the cyclin D1 gene at a glance","volume":"121","author":"Klein","year":"2008","journal-title":"J Cell Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/eem.11.25","article-title":"Progesterone receptor action: defining a role in breast cancer","volume":"6","author":"Daniel","year":"2011","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1097-2765(01)00304-5","article-title":"Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases","volume":"8","author":"Boonyaratanakornkit","year":"2001","journal-title":"Mol Cell"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100087_bib37","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1210\/en.2004-1535","article-title":"Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase\/Akt\/nuclear factor-kappaB cascade in human breast cancer cells","volume":"146","author":"Saitoh","year":"2005","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib38","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/onc.2013.579","article-title":"Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes","volume":"34","author":"Daniel","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1128\/MCB.01539-06","article-title":"Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of ERK1\/2 mitogen-activated protein kinase in breast cancer cells","volume":"27","author":"Faivre","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib40","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1158\/0008-5472.CAN-11-3290","article-title":"Estrogen receptor \u03b1 mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1\/MYC promoters","volume":"72","author":"Giulianelli","year":"2012","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib41","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.18632\/oncotarget.2354","article-title":"Acquired convergence of hormone signaling in breast cancer: ER and PR transition from functionally distinct in normal breast to predictors of metastatic disease","volume":"5","author":"Hilton","year":"2014","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib42","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/modpathol.2011.54","article-title":"Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses\u2019 Health Study","volume":"24","author":"Collins","year":"2011","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib43","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/me.2012-1107","article-title":"Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?","volume":"26","author":"Hickey","year":"2012","journal-title":"Mol Endocrinol"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100087_bib44","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-09-0452","article-title":"Androgen receptor inhibits estrogen receptor-\u03b1 activity and is prognostic in breast cancer","volume":"69","author":"Peters","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharmr.2025.100087_bib45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","article-title":"Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype","volume":"68","author":"Gerratana","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccr.2011.05.026","article-title":"Targeting androgen receptor in estrogen receptor-negative breast cancer","volume":"20","author":"Ni","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-009-0436-8","article-title":"Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells","volume":"121","author":"De Amicis","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10549-009-0400-7","article-title":"Prolactin and estradiol utilize distinct mechanisms to increase serine-118 phosphorylation and decrease levels of estrogen receptor \u03b1 in T47D breast cancer cells","volume":"120","author":"Chen","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib49","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/onc.2008.473","article-title":"Activation of the unliganded estrogen receptor by prolactin in breast cancer cells","volume":"28","author":"Gonz\u00e1lez","year":"2009","journal-title":"Oncogene"},{"issue":"27","key":"10.1016\/j.pharmr.2025.100087_bib50","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1074\/jbc.M512826200","article-title":"A novel estradiol\/estrogen receptor \u03b1-dependent transcriptional mechanism controls expression of the human prolactin receptor","volume":"281","author":"Dong","year":"2006","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib51","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1210\/me.2004-0339","article-title":"Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1\/2-mediated signals to c-fos","volume":"19","author":"Gutzman","year":"2005","journal-title":"Mol Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib52","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1677\/ERC-09-0326","article-title":"Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells","volume":"17","author":"Rasmussen","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib54","doi-asserted-by":"crossref","first-page":"530","DOI":"10.37349\/emed.2024.00237","article-title":"Structural biology of HER2\/ERBB2 dimerization: mechanistic insights and differential roles in healthy versus cancerous cells","volume":"5","author":"Santhanakrishnan","year":"2024","journal-title":"Explor Med"},{"issue":"45","key":"10.1016\/j.pharmr.2025.100087_bib55","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib56","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","article-title":"Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities","volume":"19","author":"Xu","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pharmr.2025.100087_bib57","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2407-13-174","article-title":"The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer","volume":"13","author":"Loh","year":"2013","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/\u03b2-catenin signaling in development and disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1242\/dev.013540","article-title":"Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation\/activation via frizzled, dishevelled and axin functions","volume":"135","author":"Zeng","year":"2008","journal-title":"Development"},{"issue":"5831","key":"10.1016\/j.pharmr.2025.100087_bib60","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1126\/science.1137065","article-title":"Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation","volume":"316","author":"Bilic","year":"2007","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib61","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0092-8674(02)00685-2","article-title":"Control of \u03b2-catenin phosphorylation\/degradation by a dual-kinase mechanism","volume":"108","author":"Liu","year":"2002","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib62","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib63","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/jpm11080808","article-title":"Breast cancer treatments: updates and new challenges","volume":"11","author":"Burguin","year":"2021","journal-title":"J Pers Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib64","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin-an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib65","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.pharmr.2025.100087_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1157306","article-title":"Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel","volume":"14","author":"Sousa-Pimenta","year":"2023","journal-title":"Front Pharmacol"},{"issue":"9814","key":"10.1016\/j.pharmr.2025.100087_bib67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100087_bib68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14694\/EdBook_AM.2013.33.9","article-title":"Early and late long-term effects of adjuvant chemotherapy","author":"Mayer","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.pharmr.2025.100087_bib69","first-page":"23","article-title":"Roles of multidrug resistance genes in breast cancer chemoresistance","volume":"vol 608","author":"Kuo","year":"2007"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib70","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.drudis.2021.09.020","article-title":"Advances in understanding the role of P-gp in doxorubicin resistance: molecular pathways, therapeutic strategies, and prospects","volume":"27","author":"Mirzaei","year":"2022","journal-title":"Drug Discov Today"},{"issue":"44","key":"10.1016\/j.pharmr.2025.100087_bib71","doi-asserted-by":"crossref","first-page":"31761","DOI":"10.1074\/jbc.M113.514091","article-title":"P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration","volume":"288","author":"Yamagishi","year":"2013","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib72","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4155\/fmc.15.93","article-title":"Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies","volume":"7","author":"Fan","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.pharmr.2025.100087_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.592912","article-title":"Progress in the understanding of the mechanism of tamoxifen resistance in breast cancer","volume":"11","author":"Yao","year":"2020","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107369","article-title":"Disruption of the ER-\u03b136-EGFR\/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells","volume":"9","author":"Yin","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib75","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res"},{"issue":"28","key":"10.1016\/j.pharmr.2025.100087_bib76","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/s41388-019-0817-3","article-title":"The miR-186-3p\/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells","volume":"38","author":"He","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmr.2025.100087_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/CMAR.S226410","article-title":"ER\u03b136 as a potential therapeutic target for tamoxifen-resistant breast cancer cell line through EGFR\/ERK signaling pathway","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100087_bib78","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/s41388-017-0027-9","article-title":"IGF1R signaling drives antiestrogen resistance through PAK2\/PIX activation in luminal breast cancer","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib79","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1210\/en.2007-0240","article-title":"Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells","volume":"148","author":"Song","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2025.100087_bib80","first-page":"203","article-title":"Clinical potential of novel therapeutic targets in breast cancer: CDK4\/6, Src, JAK\/STAT, PARP, HDAC, and PI3K\/AKT\/mTOR pathways","volume":"7","author":"Hosford","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib81","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.3390\/cancers13184685","article-title":"Crosstalk between PRLR and EGFR\/HER2 signaling pathways in breast cancer","volume":"13","author":"Kavarthapu","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib82","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbadis.2016.02.008","article-title":"The p21-activated kinase, PAK2, is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis events","volume":"1862","author":"Nuche-Berenguer","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-012-2376-y","article-title":"Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit","volume":"137","author":"Bostner","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib84","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00432-018-2810-6","article-title":"PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer","volume":"145","author":"Karlsson","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib85","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/cancers14040954","article-title":"Hyperactivation of MAPK induces tamoxifen resistance in SPRED2-deficient ER\u03b1-positive breast cancer","volume":"14","author":"Vafeiadou","year":"2022","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100087_bib86","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/jnci\/djp412","article-title":"Estrogen receptor-\u03b1 phosphorylation at serine-118 and tamoxifen response in breast cancer","volume":"101","author":"Kok","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib87","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1210\/me.2004-0298","article-title":"The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (\u03b1) promoter interaction and elevated steroid receptor coactivator 1 activity","volume":"19","author":"Shah","year":"2005","journal-title":"Mol Endocrinol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100087_bib88","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrc1211","article-title":"Aromatase inhibitors for breast cancer: lessons from the laboratory","volume":"3","author":"Johnston","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100087_bib89","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib90","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib91","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1073\/pnas.1322910111","article-title":"The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor \u03b1 AF-2 is modified","volume":"111","author":"Mov\u00e9rare-Skrtic","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of fulvestrant in breast cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib93","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib94","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mds328","article-title":"Pertuzumab: new hope for patients with HER2-positive breast cancer","volume":"24","author":"Capelan","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100087_bib96","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res"},{"issue":"17\u201318","key":"10.1016\/j.pharmr.2025.100087_bib97","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.drudis.2011.06.003","article-title":"Truncated HER2: implications for HER2-targeted therapeutics","volume":"16","author":"Zagozdzon","year":"2011","journal-title":"Drug Discov Today"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100087_bib98","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Lu","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib99","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1158\/0008-5472.CAN-07-5962","article-title":"Met receptor contributes to trastuzumab resistance of HER2-overexpressing breast cancer cells","volume":"68","author":"Shattuck","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib100","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/s41467-021-23052-9","article-title":"Disruption of FOXO3a-miRNA feedback inhibition of IGF2\/IGF-1R\/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer","volume":"12","author":"Luo","year":"2021","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100087_bib101","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib102","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib103","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase","volume":"108","author":"Garrett","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9712","key":"10.1016\/j.pharmr.2025.100087_bib104","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib105","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib107","doi-asserted-by":"crossref","first-page":"27","DOI":"10.37349\/etat.2022.00069","article-title":"New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development","volume":"3","author":"Koster","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib108","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib109","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib110","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib111","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2868","article-title":"Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo","volume":"13","author":"Barok","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100087_bib112","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100087_bib113","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib114","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2012.44.9694","article-title":"Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"31","author":"Hurvitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib115","first-page":"83","article-title":"Antibody-drug conjugates in breast cancer: advances and prospects","volume":"22","author":"Shi","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"10371","key":"10.1016\/j.pharmr.2025.100087_bib116","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib117","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib118","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib119","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1358\/dot.2018.55.9.3039669","article-title":"Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors","volume":"55","author":"Fenn","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41523-021-00341-6","article-title":"Oncogene-mediated metabolic gene signature predicts breast cancer outcome","volume":"7","author":"Aslan","year":"2021","journal-title":"npj Breast Cancer"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100087_bib122","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib123","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives (review)","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib124","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40265-025-02185-x","article-title":"Datopotamab deruxtecan: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2025.100087_bib125","article-title":"Safety evaluation of datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis","volume":"37","author":"Gadaleta-Caldarola","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib126","first-page":"159","article-title":"FDA approves TROP2-targeted antibody-drug conjugate for breast cancer","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib127","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/fon-2023-0188","article-title":"TROPION-Breast01: datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+\/HER2\u2212 breast cancer","volume":"20","author":"Bardia","year":"2024","journal-title":"Future Oncol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib128","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody\u2013drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmr.2025.100087_bib129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28385","article-title":"Datopotamab deruxtecan: a novel antibody drug conjugate for triple-negative breast cancer","volume":"10","author":"Schipilliti","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib131","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.pharmr.2025.100087_bib132","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2217\/fon-2023-0228","article-title":"TROPION-Breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"19","author":"Dent","year":"2023","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib133","first-page":"124","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib134","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib135","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100087_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: a comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib137","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.3390\/curroncol30090582","article-title":"Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a Canadian perspective","volume":"30","author":"Henning","year":"2023","journal-title":"Curr Oncol"},{"issue":"16 suppl","key":"10.1016\/j.pharmr.2025.100087_bib138","article-title":"First-in-human study of JSKN016, a bispecific anti-TROP2\/HER3 antibody drug conjugate (ADC): antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results","volume":"43","author":"Yao","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8 suppl 1","key":"10.1016\/j.pharmr.2025.100087_bib139","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1158\/1538-7445.AM2025-2888","article-title":"Abstract 2888: DB-1418, a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, demonstrates superior and broad antitumor efficacy and favorable safety in preclinical models","volume":"85","author":"Zhou","year":"2025","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"12 suppl","key":"10.1016\/j.pharmr.2025.100087_bib141","article-title":"Abstract P5-07-27: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: updated results from a phase 1 study","volume":"31","author":"Wu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib142","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-025-00121-y","article-title":"Dual-payload ADCs move into first oncology clinical trials","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmr.2025.100087_bib143","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211010117","article-title":"Nanobody conjugates for targeted cancer therapy and imaging","volume":"20","author":"Kang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.pharmr.2025.100087_bib144","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.pharmr.2025.100087_bib145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2021.05.004","article-title":"Nanobodies as efficient drug-carriers: progress and trends in chemotherapy","volume":"334","author":"Panikar","year":"2021","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib146","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","article-title":"Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies","volume":"56","author":"Roovers","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib147","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1517\/14712598.2013.800478","article-title":"Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target","volume":"13","author":"De Vos","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100087_bib148","doi-asserted-by":"crossref","first-page":"30297","DOI":"10.1021\/acsami.7b05654","article-title":"Quantum-dot-based theranostic micelles conjugated with an anti-EGFR nanobody for triple-negative breast cancer therapy","volume":"9","author":"Wang","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib149","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apsb.2022.07.020","article-title":"Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?","volume":"13","author":"Fu","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib150","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3390\/ijms24010829","article-title":"Peptide drug conjugates and their role in cancer therapy","volume":"24","author":"Heh","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100087_bib151","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.3390\/molecules27217232","article-title":"Peptide-drug conjugates: a new hope for cancer management","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib152","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.prro.2022.02.002","article-title":"Lutetium-177 DOTATATE: a practical review","volume":"12","author":"Jia","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.pharmr.2025.100087_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib154","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bcp.2009.12.022","article-title":"The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan","volume":"79","author":"Wickstr\u00f6m","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"39","key":"10.1016\/j.pharmr.2025.100087_bib155","doi-asserted-by":"crossref","first-page":"66641","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen\u2014a peptidase-potentiated alkylating agent in clinical trials","volume":"8","author":"Wickstr\u00f6m","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmr.2025.100087_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116119","article-title":"Peptide-drug conjugates: a new paradigm for targeted cancer therapy","volume":"265","author":"Wang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib157","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11899-022-00682-4","article-title":"The role of belantamab mafodotin, selinexor, and melflufen in multiple myeloma","volume":"17","author":"McCurdy","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib158","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1111\/cas.15086","article-title":"TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer","volume":"112","author":"Demeule","year":"2021","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib159","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.18632\/oncotarget.3401","article-title":"Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion","volume":"6","author":"Roselli","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/biomedicines9080849","article-title":"Development and characterization of a novel peptide-drug conjugate with DM1 for treatment of FGFR2-positive tumors","volume":"9","author":"Wang","year":"2021","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib161","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1021\/acs.bioconjchem.9b00755","article-title":"Targeting triple negative breast cancer cells with novel cytotoxic peptide-doxorubicin conjugates","volume":"30","author":"Ziaei","year":"2019","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib162","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/10717544.2018.1435746","article-title":"Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer","volume":"25","author":"You","year":"2018","journal-title":"Drug Deliv"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib163","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.3390\/ijms24054590","article-title":"A novel homodimer peptide-drug conjugate improves the efficacy of HER2-positive breast cancer therapy","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100087_bib164","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.biopha.2015.01.027","article-title":"Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate","volume":"70","author":"Fan","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100087_bib165","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211004954","article-title":"GE11 modified PLGA\/TPGS nanoparticles targeting delivery of salinomycin to breast cancer cells","volume":"20","author":"Li","year":"2021","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib166","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10989-023-10523-4","article-title":"Recent research progress of RGD peptide-modified nanodrug delivery systems in tumor therapy","volume":"29","author":"Yin","year":"2023","journal-title":"Int J Pept Res Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib167","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.biomaterials.2013.10.072","article-title":"Molecular basis for the targeted binding of RGD-containing peptide to integrin \u03b1V\u03b23","volume":"35","author":"Yu","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmr.2025.100087_bib168","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fonc.2013.00222","article-title":"Tumor targeting via integrin ligands","volume":"3","author":"Marelli","year":"2013","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib169","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00109-015-1279-x","article-title":"Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain","volume":"93","author":"Hamilton","year":"2015","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.pharmr.2025.100087_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109006","article-title":"Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo","volume":"116","author":"Zheng","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib171","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.573","article-title":"Complex formation of anti-VEGF-C with VEGF-C released during blood coagulation resulted in an artifact in its serum pharmacokinetics","volume":"8","author":"Bumbaca Yadav","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib172","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1039\/C5SC04392A","article-title":"Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides","volume":"7","author":"Moradi","year":"2016","journal-title":"Chem Sci"},{"key":"10.1016\/j.pharmr.2025.100087_bib173","doi-asserted-by":"crossref","DOI":"10.1038\/srep36617","article-title":"PEPlife: a repository of the half-life of peptides","volume":"6","author":"Mathur","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib174","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4062\/biomolther.2019.082","article-title":"Recent trends in cyclic peptides as therapeutic agents and biochemical tools","volume":"28","author":"Choi","year":"2020","journal-title":"Biomol Ther (Seoul)"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib175","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1021\/ac1003085","article-title":"Peptide arrays for screening cancer specific peptides","volume":"82","author":"Ahmed","year":"2010","journal-title":"Anal Chem"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100087_bib176","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1021\/jm200750x","article-title":"Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells","volume":"54","author":"Soudy","year":"2011","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib177","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1021\/acs.molpharmaceut.3c00189","article-title":"Peptide-drug conjugate targeting keratin 1 inhibits triple-negative breast cancer in mice","volume":"20","author":"Ziaei","year":"2023","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib178","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.822","article-title":"The role of cell-penetrating peptides in potential anti-cancer therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin Transl Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib179","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1021\/ja411811w","article-title":"Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ","volume":"136","author":"Yuan","year":"2014","journal-title":"J Am Chem Soc"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib180","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/anie.201107795","article-title":"Multiplex imaging of an intracellular proteolytic cascade by using a broad-spectrum nanoquencher","volume":"51","author":"Huang","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib181","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J"},{"issue":"41","key":"10.1016\/j.pharmr.2025.100087_bib182","doi-asserted-by":"crossref","first-page":"13613","DOI":"10.1039\/D1SC02973H","article-title":"Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates","volume":"12","author":"Kang","year":"2021","journal-title":"Chem Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib183","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib184","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/acs.jmedchem.0c01530","article-title":"Peptide-drug conjugates with different linkers for cancer therapy","volume":"64","author":"Alas","year":"2021","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib185","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib186","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.apsb.2023.02.013","article-title":"Research advances in peptide\u2012drug conjugates","volume":"13","author":"Gong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.pharmr.2025.100087_bib187","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11349","article-title":"Nanobodies: site-specific labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation","volume":"4","author":"Pleiner","year":"2015","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib188","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/diagnostics11091530","article-title":"Radiolabeling strategies of nanobodies for imaging applications","volume":"11","author":"K\u00fcppers","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib189","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/bc500111t","article-title":"Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging","volume":"25","author":"Massa","year":"2014","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.pharmr.2025.100087_bib190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","article-title":"Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours","volume":"317","author":"Debie","year":"2020","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib191","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00253-009-2029-1","article-title":"Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation","volume":"84","author":"Harmsen","year":"2009","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.pharmr.2025.100087_bib192","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.2147\/IJN.S164542","article-title":"Site-specific PEGylation of an anti-CEA\/CD3 bispecific antibody improves its antitumor efficacy","volume":"13","author":"Pan","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.pharmr.2025.100087_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111553","article-title":"Conjugation of oxaliplatin with pegylated-nanobody for enhancing tumor targeting and prolonging circulation","volume":"223","author":"Li","year":"2021","journal-title":"J Inorg Biochem"},{"issue":"35","key":"10.1016\/j.pharmr.2025.100087_bib194","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.1016\/j.biomaterials.2014.07.059","article-title":"Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent","volume":"35","author":"Li","year":"2014","journal-title":"Biomaterials"},{"issue":"65","key":"10.1016\/j.pharmr.2025.100087_bib195","doi-asserted-by":"crossref","first-page":"9344","DOI":"10.1039\/D0CC03396K","article-title":"Clustered nanobody-drug conjugates for targeted cancer therapy","volume":"56","author":"Wu","year":"2020","journal-title":"Chem Commun (Camb)"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100087_bib196","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.7150\/thno.57510","article-title":"Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice","volume":"11","author":"Xenaki","year":"2021","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib197","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2217\/nnm.13.86","article-title":"Nanobodies and their potential applications","volume":"8","author":"Hassanzadeh-Ghassabeh","year":"2013","journal-title":"Nanomedicine (Lond)"},{"issue":"38","key":"10.1016\/j.pharmr.2025.100087_bib198","doi-asserted-by":"crossref","first-page":"25612","DOI":"10.1074\/jbc.M109.027078","article-title":"Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives","volume":"284","author":"Stork","year":"2009","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib199","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmr.2025.100087_bib200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/DDDT.S119488","article-title":"Metal complexes in cancer therapy\u2014an update from drug design perspective","volume":"11","author":"Ndagi","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib201","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/ma14030549","article-title":"The role of metal ions in biology, biochemistry and medicine","volume":"14","author":"Moustakas","year":"2021","journal-title":"Materials (Basel)"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100087_bib202","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3390\/ijms18112285","article-title":"Zinc in cellular regulation: the nature and significance of \u201czinc signals.\u201d","volume":"18","author":"Maret","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100087_bib203","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.711227","article-title":"Role of copper on mitochondrial function and metabolism","volume":"8","author":"Ruiz","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.pharmr.2025.100087_bib204","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1203447","article-title":"Targeting copper metabolism: a promising strategy for cancer treatment","volume":"14","author":"Kong","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100087_bib205","first-page":"133","article-title":"Heavy metal toxicity and the environment","volume":"101","author":"Tchounwou","year":"2012","journal-title":"Exp Suppl"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib206","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1615\/JEnvironPatholToxicolOncol.2017025229","article-title":"Dual roles of oxidative stress in metal carcinogenesis","volume":"36","author":"Xu","year":"2017","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib207","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-019-08290-2","article-title":"Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs","volume":"10","author":"Yimit","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib208","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/acsbiomaterials.7b00921","article-title":"Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy","volume":"4","author":"Wlodarczyk","year":"2018","journal-title":"ACS Biomater Sci Eng"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100087_bib209","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","article-title":"Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity","volume":"26","author":"Volarevic","year":"2019","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib211","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1039\/C3MT00099K","article-title":"Effect of oxindolimine copper(II) and zinc(II) complexes on human topoisomerase I activity","volume":"6","author":"Katkar","year":"2014","journal-title":"Metallomics"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100087_bib212","doi-asserted-by":"crossref","first-page":"12010","DOI":"10.1074\/jbc.M610927200","article-title":"Pro-apoptotic activity of novel isatin-Schiff base copper(II) complexes depends on oxidative stress induction and organelle-selective damage","volume":"282","author":"Filomeni","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100087_bib213","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jinorgbio.2018.05.012","article-title":"Comparative studies of oxindolimine-metal complexes as inhibitors of human DNA topoisomerase IB","volume":"186","author":"Castelli","year":"2018","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.pharmr.2025.100087_bib214","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1038\/ncomms4462","article-title":"Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity","volume":"5","author":"Adhireksan","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2025.100087_bib215","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.phrs.2016.03.032","article-title":"The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells","volume":"107","author":"Montani","year":"2016","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib216","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12951-022-01404-x","article-title":"Intracellular marriage of bicarbonate and Mn ions as \u201cimmune ion reactors\u201d to regulate redox homeostasis and enhanced antitumor immune responses","volume":"20","author":"Feng","year":"2022","journal-title":"J Nanobiotechnology"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib217","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1039\/C9NA00241C","article-title":"Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells","volume":"1","author":"Avvakumova","year":"2019","journal-title":"Nanoscale Adv"},{"key":"10.1016\/j.pharmr.2025.100087_bib218","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biopha.2015.03.004","article-title":"Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells","volume":"72","author":"Huang","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100087_bib219","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.biopha.2015.05.013","article-title":"Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery","volume":"73","author":"Huang","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100087_bib220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.actbio.2015.02.022","article-title":"Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis","volume":"18","author":"Li","year":"2015","journal-title":"Acta Biomater"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib221","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acs.bioconjchem.6b00610","article-title":"Pt-Mal-LHRH, a newly synthesized compound attenuating breast cancer tumor growth and metastasis by targeting overexpression of the LHRH receptor","volume":"28","author":"Calderon","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.pharmr.2025.100087_bib222","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2019.06.031","article-title":"Rationally designed peptide-conjugated gold\/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy","volume":"308","author":"Yang","year":"2019","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib223","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1039\/C8CC08769E","article-title":"Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines","volume":"55","author":"Curado","year":"2019","journal-title":"Chem Commun (Camb)"},{"issue":"47","key":"10.1016\/j.pharmr.2025.100087_bib224","doi-asserted-by":"crossref","first-page":"12250","DOI":"10.1002\/chem.201800872","article-title":"Synthesis and biological evaluation of homogeneous thiol-linked NHC\u2217-Au-albumin and -trastuzumab bioconjugates","volume":"24","author":"Matos","year":"2018","journal-title":"Chemistry"},{"key":"10.1016\/j.pharmr.2025.100087_bib225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fbioe.2020.00132","article-title":"Extra-small gold nanospheres decorated with a Thiol functionalized biodegradable and biocompatible linear polyamidoamine as nanovectors of anticancer molecules","volume":"8","author":"Bloise","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib226","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.nucmedbio.2016.08.009","article-title":"111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection","volume":"43","author":"Cai","year":"2016","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.pharmr.2025.100087_bib227","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/IJN.S10881","article-title":"Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer","volume":"5","author":"Day","year":"2010","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.pharmr.2025.100087_bib228","article-title":"Photothermal therapeutic application of gold nanorods-porphyrin-trastuzumab complexes in HER2-positive breast cancer","volume":"7","author":"Kang","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100087_bib229","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/acs.molpharmaceut.9b00695","article-title":"Bioconjugation of Cyclometalated gold(III) lipoic acid fragments to linear and cyclic breast cancer targeting peptides","volume":"16","author":"\u015ami\u0142owicz","year":"2019","journal-title":"Mol Pharm"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100087_bib230","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/26\/19\/195101","article-title":"Breast cancer photothermal therapy based on gold nanorods targeted by covalently-coupled bombesin peptide","volume":"26","author":"Heidari","year":"2015","journal-title":"Nanotechnology"},{"issue":"27","key":"10.1016\/j.pharmr.2025.100087_bib231","doi-asserted-by":"crossref","first-page":"12858","DOI":"10.1039\/C9NR01277J","article-title":"Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells","volume":"11","author":"Ruenraroengsak","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.pharmr.2025.100087_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113357","article-title":"Peptide-functionalized zinc oxide nanoparticles for the selective targeting of breast cancer expressing placenta-specific protein 1","volume":"227","author":"Cagliani","year":"2023","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.pharmr.2025.100087_bib233","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.2147\/IJN.S175334","article-title":"Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment","volume":"13","author":"Li","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.pharmr.2025.100087_bib234","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jinorgbio.2018.06.009","article-title":"Selective Cu(I) complex with phosphine-peptide (SarGly) conjugate contra breast cancer: synthesis, spectroscopic characterization and insight into cytotoxic action","volume":"186","author":"Komarnicka","year":"2018","journal-title":"J Inorg Biochem"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib235","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1039\/D0DT00955E","article-title":"Novel \u201cruthenium cyclopentadienyl\u201d-peptide conjugate complexes against human FGFR(+) breast cancer","volume":"49","author":"Franco Machado","year":"2020","journal-title":"Dalton Trans"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib236","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1039\/D4DT00497C","article-title":"Dual FGFR-targeting and pH-activatable ruthenium-peptide conjugates for targeted therapy of breast cancer","volume":"53","author":"Franco Machado","year":"2024","journal-title":"Dalton Trans"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib237","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2015.06.012","article-title":"An integrated view of cisplatin-induced nephrotoxicity and ototoxicity","volume":"237","author":"Karasawa","year":"2015","journal-title":"Toxicol Lett"},{"issue":"40","key":"10.1016\/j.pharmr.2025.100087_bib238","doi-asserted-by":"crossref","first-page":"14224","DOI":"10.1002\/anie.201909345","article-title":"A nanobody-conjugated DNA nanoplatform for targeted platinum-drug delivery","volume":"58","author":"Wu","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100087_bib239","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1039\/c4tb00077c","article-title":"LHRH-peptide conjugated dextran nanoparticles for targeted delivery of cisplatin to breast cancer","volume":"2","author":"Li","year":"2014","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.pharmr.2025.100087_bib240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-0-387-74911-2_32","article-title":"LHRH receptor targeted therapy for breast cancer","volume":"614","author":"Kakar","year":"2008","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib241","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287151","article-title":"Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer","volume":"18","author":"Ndinguri","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100087_bib242","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fchem.2020.00543","article-title":"Recent advances of Gold Compounds in anticancer immunity","volume":"8","author":"Yue","year":"2020","journal-title":"Front Chem"},{"key":"10.1016\/j.pharmr.2025.100087_bib243","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.saa.2013.03.037","article-title":"Synthesis and evaluation of gold(III) complexes as efficient DNA binders and cytotoxic agents","volume":"110","author":"Patel","year":"2013","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"10.1016\/j.pharmr.2025.100087_bib244","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jinorgbio.2013.09.019","article-title":"Strong inhibition of thioredoxin reductase by highly cytotoxic gold(I) complexes. DNA binding studies","volume":"130","author":"Ortego","year":"2014","journal-title":"J Inorg Biochem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib245","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1021\/acs.inorgchem.0c00423","article-title":"Antitumor and antiangiogenic properties of gold(III) complexes containing Cycloaurated triphenylphosphine sulfide ligands","volume":"59","author":"Srinivasa Reddy","year":"2020","journal-title":"Inorg Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib246","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2741\/4364","article-title":"Matrix metalloproteinases as breast cancer drivers and therapeutic targets","volume":"20","author":"Radisky","year":"2015","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib247","first-page":"1139","article-title":"Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[d-TYR6, \u03b2-ALA11, PHE13, NLE14] bombesin(6\u201314)","volume":"8","author":"Reubi","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib248","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20892\/j.issn.2095-3941.2017.0086","article-title":"PD-1\/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy","volume":"15","author":"Jia","year":"2018","journal-title":"Cancer Biol Med"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib249","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/genes8100281","article-title":"Eco-friendly formulated zinc oxide nanoparticles: induction of cell cycle arrest and apoptosis in the MCF-7 cancer cell line","volume":"8","author":"Boroumand Moghaddam","year":"2017","journal-title":"Genes"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib250","doi-asserted-by":"crossref","first-page":"17984","DOI":"10.1002\/jcb.29065","article-title":"Green synthesized-zinc oxide nanoparticles, the strong apoptosis inducer as an exclusive antitumor agent in murine breast tumor model and human breast cancer cell lines (MCF7)","volume":"120","author":"Mahdizadeh","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.pharmr.2025.100087_bib251","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.freeradbiomed.2016.11.048","article-title":"PEG-functionalized zinc oxide nanoparticles induce apoptosis in breast cancer cells through reactive oxygen species-dependent impairment of DNA damage repair enzyme NEIL2","volume":"103","author":"Chakraborti","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib252","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12964-020-00646-2","article-title":"Non-canonical Fzd7 signaling contributes to breast cancer mesenchymal-like stemness involving Col6a1","volume":"18","author":"Yin","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib253","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/1878-0261.12311","article-title":"Cancer\/testis antigen-Plac1 promotes invasion and metastasis of breast cancer through Furin\/NICD\/PTEN signaling pathway","volume":"12","author":"Li","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.pharmr.2025.100087_bib254","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5772\/63437","article-title":"ZnO nanoparticles: a promising anticancer agent","volume":"3","author":"Bisht","year":"2016","journal-title":"Nanobiomedicine"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/toxres\/tfaa090","article-title":"Silver nanoparticles achieve cytotoxicity against breast cancer by regulating long-chain noncoding RNA XLOC_006390-mediated pathway","volume":"10","author":"Tao","year":"2021","journal-title":"Toxicol Res (Camb)"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib256","article-title":"Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells","volume":"2013","author":"Gurunathan","year":"2013","journal-title":"BioMed Res Int"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib257","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13237-019-00305-z","article-title":"Cytotoxic effect of green synthesized silver nanoparticles in MCF7 and MDA-MB-231 human breast cancer cells in vitro","volume":"63","author":"Bandyopadhyay","year":"2020","journal-title":"Nucleus"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib258","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1515\/ntrev-2022-0021","article-title":"Octreotide-conjugated silver nanoparticles for active targeting of somatostatin receptors and their application in a nebulized rat model","volume":"11","author":"Abdellatif","year":"2022","journal-title":"Nanotechnol Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib259","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","article-title":"Copper homeostasis and cuproptosis in health and disease","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib260","first-page":"1143","article-title":"Iron metabolism and its contribution to cancer (review)","volume":"54","author":"Chen","year":"2019","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib261","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12094-011-0621-1","article-title":"The role of iron in tumour cell proliferation","volume":"13","author":"Steegmann-Olmedillas","year":"2011","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib262","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1038\/s41467-021-27559-z","article-title":"Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis","volume":"12","author":"Ramchandani","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib263","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41587-020-0707-9","article-title":"Mitochondrial copper depletion suppresses triple-negative breast cancer in mice","volume":"39","author":"Cui","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib264","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40170-022-00284-x","article-title":"An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells","volume":"10","author":"Fujisawa","year":"2022","journal-title":"Cancer Metab"},{"key":"10.1016\/j.pharmr.2025.100087_bib265","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.1005092","article-title":"Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines","volume":"9","author":"Abdelaal","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib266","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1385\/BTER:103:3:229","article-title":"Copper increases the damage to DNA and proteins caused by reactive oxygen species","volume":"103","author":"Cervantes-Cervantes","year":"2005","journal-title":"Biol Trace Elem Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib267","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/bjc.2011.126","article-title":"Disulfiram modulated ROS-MAPK and NF\u03baB pathways and targeted breast cancer cells with cancer stem cell-like properties","volume":"104","author":"Yip","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharmr.2025.100087_bib268","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2023.112335","article-title":"Memo1 reduces copper-mediated reactive oxygen species in breast cancer cells","volume":"247","author":"Zhang","year":"2023","journal-title":"J Inorg Biochem"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib269","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1039\/C7DT00283A","article-title":"Copper(II) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells","volume":"46","author":"S\u00eerbu","year":"2017","journal-title":"Dalton Trans"},{"issue":"37","key":"10.1016\/j.pharmr.2025.100087_bib270","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1039\/C8NR05150J","article-title":"Development of a novel FePt-based multifunctional ferroptosis agent for high-efficiency anticancer therapy","volume":"10","author":"Yue","year":"2018","journal-title":"Nanoscale"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100087_bib271","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1158\/0008-5472.CAN-11-1218","article-title":"Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes","volume":"71","author":"Lovejoy","year":"2011","journal-title":"Cancer Res"},{"issue":"6586","key":"10.1016\/j.pharmr.2025.100087_bib272","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib273","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202213922","article-title":"Photothermally triggered copper payload release for cuproptosis-promoted cancer synergistic therapy","volume":"62","author":"Zhou","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib274","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","article-title":"Ferroptosis: death by lipid peroxidation","volume":"26","author":"Yang","year":"2016","journal-title":"Trends Cell Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib275","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2967\/jnumed.107.048231","article-title":"Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+\/peptide transporter","volume":"49","author":"Mitsuoka","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pharmr.2025.100087_bib276","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3389\/fphar.2018.01323","article-title":"Applications of ruthenium complex in tumor diagnosis and therapy","volume":"9","author":"Lin","year":"2018","journal-title":"Front Pharmacol"},{"issue":"43","key":"10.1016\/j.pharmr.2025.100087_bib277","doi-asserted-by":"crossref","first-page":"15308","DOI":"10.1002\/chem.201502154","article-title":"Cyclometalated ruthenium(II) anthraquinone complexes exhibit strong anticancer activity in hypoxic tumor cells","volume":"21","author":"Zeng","year":"2015","journal-title":"Chemistry"},{"key":"10.1016\/j.pharmr.2025.100087_bib278","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1038\/srep09157","article-title":"Ruthenium polypyridyl complex inhibits growth and metastasis of breast cancer cells by suppressing FAK signaling with enhancement of TRAIL-induced apoptosis","volume":"5","author":"Cao","year":"2015","journal-title":"Sci Rep"},{"issue":"50","key":"10.1016\/j.pharmr.2025.100087_bib279","doi-asserted-by":"crossref","first-page":"20376","DOI":"10.1021\/ja307288s","article-title":"Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid","volume":"134","author":"Pierroz","year":"2012","journal-title":"J Am Chem Soc"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib280","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00775-013-1069-2","article-title":"Mitochondria are the primary target in the induction of apoptosis by chiral ruthenium(II) polypyridyl complexes in cancer cells","volume":"19","author":"Wang","year":"2014","journal-title":"J Biol Inorg Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib281","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib282","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib283","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib284","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.pharmr.2025.100087_bib285","first-page":"22","article-title":"Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer","volume":"7","author":"Saleh","year":"2024","journal-title":"Cancer Drug Resist"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100087_bib286","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to trastuzumab in breast cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib287","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","article-title":"Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy","volume":"11","author":"Wu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib288","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib289","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib290","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1535-7163.MCT-16-0658","article-title":"Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs","volume":"16","author":"Andreev","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharmr.2025.100087_bib291","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113050","article-title":"Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment","volume":"213","author":"Deng","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib292","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pharmr.2025.100087_bib293","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102902","article-title":"Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target","volume":"134","author":"Mountzios","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib294","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2022.130152","article-title":"The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells","volume":"1866","author":"Dharmasivam","year":"2022","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib295","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bph.14985","article-title":"Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC","volume":"177","author":"Maqbool","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100087_bib296","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/jm300768u","article-title":"Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo","volume":"55","author":"Lovejoy","year":"2012","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib297","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood-2004-03-0868","article-title":"Novel di-2-pyridyl\u2013derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment","volume":"104","author":"Yuan","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100087_bib298","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm900552r","article-title":"Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors","volume":"52","author":"Yu","year":"2009","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100087_bib299","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1021\/jm0606342","article-title":"Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity","volume":"49","author":"Richardson","year":"2006","journal-title":"J Med Chem"},{"issue":"40","key":"10.1016\/j.pharmr.2025.100087_bib300","doi-asserted-by":"crossref","first-page":"14901","DOI":"10.1073\/pnas.0604979103","article-title":"A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics","volume":"103","author":"Whitnall","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib301","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.112.078964","article-title":"Methemoglobin formation by Triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect","volume":"82","author":"Quach","year":"2012","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib302","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-016-0330-x","article-title":"The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms","volume":"9","author":"Guo","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib303","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002279R","article-title":"Breaking the cycle: targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma","volume":"35","author":"Geleta","year":"2021","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib304","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","article-title":"Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer","volume":"80","author":"Kovacevic","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib305","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1074\/jbc.M115.689653","article-title":"The metastasis suppressor, N-MYC downstream-regulated Gene-1 (NDRG1), down-regulates the ErbB family of receptors to inhibit downstream oncogenic signaling pathways","volume":"291","author":"Kovacevic","year":"2016","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib306","first-page":"5370","article-title":"The iron chelator Dp44mT suppresses osteosarcoma\u2019s proliferation, invasion and migration: in vitro and in vivo","volume":"8","author":"Li","year":"2016","journal-title":"Am J Transl Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib307","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1039\/D0NH00148A","article-title":"Enhancing the chemotherapeutic efficacy of platinum prodrug nanoparticles and inhibiting cancer metastasis by targeting iron homeostasis","volume":"5","author":"Ding","year":"2020","journal-title":"Nanoscale Horiz"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib308","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.18632\/oncotarget.2328","article-title":"The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)\/gp130\/STAT3 pathway","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib309","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13402-020-00502-y","article-title":"Dp44mT, an iron chelator, suppresses growth and induces apoptosis via RORA-mediated NDRG2-IL6\/JAK2\/STAT3 signaling in glioma","volume":"43","author":"Zhou","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib310","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/emmm.201100190","article-title":"N-myc downstream regulated gene 1 modulates Wnt-\u03b2-catenin signalling and pleiotropically suppresses metastasis","volume":"4","author":"Liu","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"40","key":"10.1016\/j.pharmr.2025.100087_bib311","doi-asserted-by":"crossref","first-page":"42411","DOI":"10.18632\/oncotarget.6389","article-title":"Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents","volume":"6","author":"Sestak","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmr.2025.100087_bib312","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105889","article-title":"Innovative therapies for neuroblastoma: the surprisingly potent role of iron chelation in up-regulating metastasis and tumor suppressors and down-regulating the key oncogene, N-myc","volume":"173","author":"Wijesinghe","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmr.2025.100087_bib313","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.phrs.2015.08.013","article-title":"The renaissance of polypharmacology in the development of anti-cancer therapeutics: inhibition of the \u201cTriad of Death\u201d in cancer by di-2-pyridylketone thiosemicarbazones","volume":"100","author":"Jansson","year":"2015","journal-title":"Pharmacol Res"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100087_bib314","doi-asserted-by":"crossref","first-page":"15453","DOI":"10.1021\/acs.jmedchem.3c01612","article-title":"Steric blockade of oxy-myoglobin oxidation by thiosemicarbazones: structure-activity relationships of the novel PPP4pT series","volume":"66","author":"Wijesinghe","year":"2023","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib315","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1021\/acs.jmedchem.2c01600","article-title":"Designing tailored thiosemicarbazones with bespoke properties: the styrene moiety imparts potent activity, inhibits heme center oxidation, and results in a novel \u201cstealth zinc(II) complex.\u201d","volume":"66","author":"Dharmasivam","year":"2023","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100087_bib316","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-19-0096","article-title":"COTI-2, A Novel thiosemicarbazone Derivative, Exhibits antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms","volume":"25","author":"Lindemann","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib317","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00280-016-3200-x","article-title":"Phase I trial of daily Triapine in combination with cisplatin chemotherapy for advanced-stage malignancies","volume":"79","author":"Kunos","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib318","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1021\/acs.jmedchem.5c00374","article-title":"Advantages of novel anti-cancer Selenosemicarbazones: preferential reactivity of their Fe(III), Cu(II), and Zn(II) complexes with key physiological reductants\/ligands versus isosteric thiosemicarbazones","volume":"68","author":"Dharmasivam","year":"2025","journal-title":"J Med Chem"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100087_bib319","doi-asserted-by":"crossref","first-page":"12155","DOI":"10.1021\/acs.jmedchem.4c00884","article-title":"Isosteric replacement of sulfur to selenium in a thiosemicarbazone: promotion of Zn (II) complex dissociation and Transmetalation to augment anticancer efficacy","volume":"67","author":"Kaya","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100087_bib320","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1615\/CritRevOncog.2013007784","article-title":"Cellular iron metabolism in prognosis and therapy of breast cancer","volume":"18","author":"Torti","year":"2013","journal-title":"Crit Rev Oncog"},{"issue":"63","key":"10.1016\/j.pharmr.2025.100087_bib321","doi-asserted-by":"crossref","first-page":"107052","DOI":"10.18632\/oncotarget.22323","article-title":"Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients","volume":"8","author":"Greene","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100087_bib322","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100087_bib323","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib324","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12935-024-03259-8","article-title":"Targeted drug delivery using nanobodies to deliver effective molecules to breast cancer cells: the most attractive application of nanobodies","volume":"24","author":"Abdolvahab","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib325","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1074\/jbc.RA119.011341","article-title":"Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding","volume":"295","author":"Park","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100087_bib326","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.freeradbiomed.2019.05.020","article-title":"Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer","volume":"157","author":"Park","year":"2020","journal-title":"Free Radic Biol Med"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100087_bib327","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.3390\/cancers14235739","article-title":"NDRG1 in cancer: a suppressor, promoter, or both?","volume":"14","author":"Joshi","year":"2022","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100087_bib328","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1007\/s00018-016-2313-z","article-title":"Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression","volume":"73","author":"Lee","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib329","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","article-title":"Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis","volume":"14","author":"Yang","year":"2008","journal-title":"Dev Cell"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib330","first-page":"293","article-title":"Metastasis mechanisms","volume":"1796","author":"Geiger","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100087_bib331","doi-asserted-by":"crossref","first-page":"17016","DOI":"10.1074\/jbc.M112.350470","article-title":"The iron chelators Dp44mT and DFO inhibit TGF-\u03b2-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1)","volume":"287","author":"Chen","year":"2012","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100087_bib332","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/carcin\/bgy178","article-title":"The metastasis suppressor, NDRG1, attenuates oncogenic TGF-\u03b2 and NF-\u03baB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells","volume":"40","author":"Menezes","year":"2019","journal-title":"Carcinogenesis"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100087_bib333","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2004-05-1866","article-title":"Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation","volume":"104","author":"Le","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100087_bib334","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057273","article-title":"N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion","volume":"8","author":"Lane","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100087_bib335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107417","article-title":"Multi-modal mechanisms of the metastasis suppressor, NDRG1: inhibition of WNT\/\u03b2-catenin signaling by stabilization of protein kinase C\u03b1","volume":"300","author":"Gholam Azad","year":"2024","journal-title":"J Biol Chem"},{"issue":"31","key":"10.1016\/j.pharmr.2025.100087_bib336","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1074\/jbc.R117.776393","article-title":"Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling","volume":"292","author":"Menezes","year":"2017","journal-title":"J Biol Chem"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100087_bib337","doi-asserted-by":"crossref","first-page":"7655","DOI":"10.1158\/0008-5472.CAN-04-1623","article-title":"PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer","volume":"64","author":"Bandyopadhyay","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib338","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1089\/ars.2011.4273","article-title":"The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways","volume":"18","author":"Kovacevic","year":"2013","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib339","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials","volume":"10","author":"Song","year":"2023","journal-title":"Genes Dis"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100087_bib340","doi-asserted-by":"crossref","first-page":"16049","DOI":"10.18632\/oncotarget.7533","article-title":"Estrogen receptor alpha (ER\u03b1\/ESR1) mediates the p53-independent overexpression of MDM4\/MDMX and MDM2 in human breast cancer","volume":"7","author":"Swetzig","year":"2016","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100087_bib341","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/onc.2011.370","article-title":"Macrophage-elicited loss of estrogen receptor-\u03b1 in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus","volume":"31","author":"Stossi","year":"2012","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib342","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac122","article-title":"Breast cancer and prolactin\u2014new mechanisms and models","volume":"163","author":"Clevenger","year":"2022","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100087_bib343","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.381","article-title":"A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC","volume":"7","author":"Seebacher","year":"2016","journal-title":"Cell Death Dis"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100087_bib344","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1074\/jbc.M114.631283","article-title":"Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp)","volume":"290","author":"Jansson","year":"2015","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100087_bib345","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1074\/jbc.M115.682450","article-title":"Glucose modulation induces lysosome formation and increases lysosomotropic drug sequestration via the P-glycoprotein drug transporter","volume":"291","author":"Seebacher","year":"2016","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100087_bib346","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1074\/jbc.RA118.006279","article-title":"The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6","volume":"294","author":"Menezes","year":"2019","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100087_bib347","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1021\/jm100561b","article-title":"Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity","volume":"53","author":"Jansson","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100087_bib348","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2019.110780","article-title":"Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer","volume":"199","author":"Del Solar","year":"2019","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.pharmr.2025.100087_bib349","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2023.215579","article-title":"Riding the metal wave: a review of the latest developments in metal-based anticancer agents","volume":"501","author":"Abdolmaleki","year":"2024","journal-title":"Coord Chem Rev"},{"issue":"37","key":"10.1016\/j.pharmr.2025.100087_bib350","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1039\/D4SC04339A","article-title":"Targeting lysosomes by design: novel N-acridine thiosemicarbazones that enable direct detection of intracellular drug localization and overcome P-glycoprotein (Pgp)-mediated resistance","volume":"15","author":"Kaya","year":"2024","journal-title":"Chem Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100087_bib351","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1021\/acs.jmedchem.6b00238","article-title":"Zinc(II)\u2013thiosemicarbazone complexes are localized to the lysosomal compartment where they transmetallate with copper ions to induce cytotoxicity","volume":"59","author":"Stacy","year":"2016","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100087_bib352","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/acs.jmedchem.5b01399","article-title":"Novel mechanism of cytotoxicity for the selective selenosemicarbazone, 2-acetylpyridine 4,4-dimethyl-3-selenosemicarbazone (Ap44mSe): lysosomal membrane permeabilization","volume":"59","author":"Al-Eisawi","year":"2016","journal-title":"J Med Chem"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:38:31Z","timestamp":1778636311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725074952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":352,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0031699725074952"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100087","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metal-based antibody, nanobody, and peptide conjugates: Potential for breast cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100087"}}